Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
2020 · Nature Metabolism · 747 citations
https://doi.org/10.1038/s42255-020-00287-2
J
Jeremy D. Gale
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
83
Papers
2.6K
Citations
24
h-index
38
i10-index
Jeremy D. Gale is an academic researcher from Pfizer (United States). The author has contributed to research in topics: Gastrointestinal motility and disorders & Inflammatory Bowel Disease & Microscopic Colitis. The author has an h-index of 24, co-authored 71 publications.
Papers by this author
worksEffect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy
2018 · Kidney International Reports · 49 citations
https://doi.org/10.1016/j.ekir.2018.07.010
Multimodal sensory testing of the rectum and rectosigmoid: development and reproducibility of a new method
2008 · Neurogastroenterology & Motility · 44 citations
https://doi.org/10.1111/j.1365-2982.2008.01126.x
Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome
2025 · Alimentary Pharmacology & Therapeutics · 5 citations
https://doi.org/10.1111/apt.18487
Efficacy and safety of the interleukin-10–fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial
2026 · Therapeutic Advances in Gastroenterology · 0 citations
https://doi.org/10.1177/17562848251410784
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat